eflornithine has been researched along with Hypertension in 5 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These studies indicate that normalization of vascular function can occur in the presence of significantly elevated blood pressure upon chronic administration of eflornithine." | 5.30 | Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. ( Aziz, SM; Lipke, DW; Newman, PS; Soltis, EE; Tofiq, S, 1997) |
| " The effects of chronic administration of eflornithine (alpha-difluoromethylornithine; DFMO), a highly specific inhibitor of ornithine decarboxylase (the rate limiting enzyme in polyamine biosynthesis), on vascular polyamine contents, vascular structure and function, and blood pressure was studied." | 5.29 | Eflornithine treatment in SHR: potential role of vascular polyamines and ornithine decarboxylase in hypertension. ( Newman, PS; Olson, JW; Soltis, EE, 1994) |
| " This study examined the effects of polyamine synthesis inhibition using eflornithine, a suicide inhibitor of ornithine decarboxylase on blood pressure, compensatory remodeling of the cardiovascular system, and cardiac and aortic polyamine contents using an aortic coarctation model in rats." | 3.69 | Multiple polyamine regulatory pathways control compensatory cardiovascular hypertrophy in coarctation hypertension. ( Arcot, SS; Aziz, SM; Guo, H; Lipke, DW; Newman, PS; Olson, JW; Soltis, EE; Tofiq, S, 1997) |
| "A decrease in nitric oxide (NO) bioavailability has been proposed to contribute to endothelial dysfunction and increased peripheral resistances during essential arterial hypertension." | 1.33 | Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. ( Berthelot, A; Demougeot, C; Marie, C; Prigent-Tessier, A, 2005) |
| " These studies indicate that normalization of vascular function can occur in the presence of significantly elevated blood pressure upon chronic administration of eflornithine." | 1.30 | Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. ( Aziz, SM; Lipke, DW; Newman, PS; Soltis, EE; Tofiq, S, 1997) |
| " The effects of chronic administration of eflornithine (alpha-difluoromethylornithine; DFMO), a highly specific inhibitor of ornithine decarboxylase (the rate limiting enzyme in polyamine biosynthesis), on vascular polyamine contents, vascular structure and function, and blood pressure was studied." | 1.29 | Eflornithine treatment in SHR: potential role of vascular polyamines and ornithine decarboxylase in hypertension. ( Newman, PS; Olson, JW; Soltis, EE, 1994) |
| " The effects of chronic administration of alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase and thus polyamine biosynthesis, on vascular polyamine contents, structure, and function as well as the development of hypertension was studied." | 1.28 | Polyamines, vascular smooth muscle, and deoxycorticosterone acetate-salt hypertension. ( Newman, PS; Olson, JW; Soltis, EE, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demougeot, C | 1 |
| Prigent-Tessier, A | 1 |
| Marie, C | 1 |
| Berthelot, A | 1 |
| Soltis, EE | 4 |
| Newman, PS | 4 |
| Olson, JW | 3 |
| Lipke, DW | 2 |
| Tofiq, S | 2 |
| Guo, H | 1 |
| Arcot, SS | 1 |
| Aziz, SM | 2 |
5 other studies available for eflornithine and Hypertension
| Article | Year |
|---|---|
Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats.
Topics: Animals; Aorta; Arginase; Blood Pressure; Eflornithine; Endothelium, Vascular; Enzyme Inhibitors; Hy | 2005 |
Eflornithine treatment in SHR: potential role of vascular polyamines and ornithine decarboxylase in hypertension.
Topics: Animals; Biogenic Polyamines; Blood Pressure; Blood Vessels; Eflornithine; Electric Stimulation; Hyp | 1994 |
Multiple polyamine regulatory pathways control compensatory cardiovascular hypertrophy in coarctation hypertension.
Topics: Animals; Aorta, Abdominal; Aortic Coarctation; Blood Pressure; Blotting, Northern; Eflornithine; Enz | 1997 |
Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension.
Topics: Acetylcholine; Animals; Aorta; Aortic Coarctation; Eflornithine; Enzyme Inhibitors; Hypertension; Mu | 1997 |
Polyamines, vascular smooth muscle, and deoxycorticosterone acetate-salt hypertension.
Topics: Acetylcholine; Animals; Aorta; Arteries; Blood Pressure; Body Weight; Desoxycorticosterone; Dose-Res | 1991 |